Angell TE - Search Results

1

Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma.

Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL. Lechner MG, et al. Among authors: angell te. Clin Cancer Res. 2012 Sep 1;18(17):4549-59. doi: 10.1158/1078-0432.CCR-12-0101. Epub 2012 Jul 12. Clin Cancer Res. 2012. PMID: 22791880

2

Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy.

Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Lechner MG, et al. Among authors: angell te. J Immunother. 2013 Nov-Dec;36(9):477-89. doi: 10.1097/01.cji.0000436722.46675.4a. J Immunother. 2013. PMID: 24145359 Free PMC article.

3

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. Angell TE, et al. Thyroid. 2014 Sep;24(9):1385-93. doi: 10.1089/thy.2014.0134. Epub 2014 Jul 15. Thyroid. 2014. PMID: 24955518 Free PMC article.

4

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.

Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. Angell TE, et al. Clin Cancer Res. 2014 Dec 1;20(23):6034-44. doi: 10.1158/1078-0432.CCR-14-0879. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294906 Free PMC article.

5

Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study.

Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Angell TE, et al. J Clin Endocrinol Metab. 2015 Feb;100(2):451-9. doi: 10.1210/jc.2014-2850. Epub 2014 Oct 24. J Clin Endocrinol Metab. 2015. PMID: 25343237

6

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. Angell TE, et al. Thyroid. 2016 Mar;26(3):381-9. doi: 10.1089/thy.2015.0289. Epub 2016 Feb 10. Thyroid. 2016. PMID: 26756227 Free PMC article.

7

Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.

Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL. Jang JK, et al. Among authors: angell te. Cancer Immunol Immunother. 2016 May;65(5):511-23. doi: 10.1007/s00262-016-1813-x. Epub 2016 Mar 9. Cancer Immunol Immunother. 2016. PMID: 26960932 Free PMC article.

8

Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.

Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. Lechner MG, et al. Among authors: angell te. Thyroid. 2018 Apr;28(4):445-453. doi: 10.1089/thy.2017.0587. Thyroid. 2018. PMID: 29652597

9

Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.

Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. Lechner MG, et al. Among authors: angell te. Thyroid. 2018 Apr;28(4):437-444. doi: 10.1089/thy.2017.0579. Thyroid. 2018. PMID: 29652599

10

Treatment of Differentiated Thyroid Carcinomas.

Lechner MG, Praw SS, Angell TE. Lechner MG, et al. Among authors: angell te. Surg Pathol Clin. 2019 Dec;12(4):931-942. doi: 10.1016/j.path.2019.08.003. Epub 2019 Sep 27. Surg Pathol Clin. 2019. PMID: 31672299 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters